Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE)
Conditions
Interventions
Atogepant
Placebo for Atogepant
Locations
149
Belgium
Universitair Ziekenhuis Antwerpen /ID# 257582
Edegem, Antwerpen, Belgium
Universitair Ziekenhuis Brussel /ID# 257584
Jette, Brussels Capital, Belgium
Cabinet Prive Dr Sava /ID# 257581
Saint-Nicolas, Liege, Belgium
Jessa Ziekenhuis /ID# 257578
Hasselt, Limburg, Belgium
AZ Sint-Jan Brugge /ID# 257585
Bruges, West-Vlaanderen, Belgium
AZ Groeninge /ID# 257586
Kortrijk, Belgium
Start Date
March 25, 2024
Primary Completion Date
July 7, 2025
Completion Date
November 1, 2026
Last Updated
April 14, 2026
NCT06735833
NCT07018713
NCT06641466
NCT04715685
NCT07476053
NCT06806293
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions